Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer

被引：62

作者：

Asano, Yuka ^{[1
]}

Kashiwagi, Shinichiro ^{[1
]}

Goto, Wataru ^{[1
]}

Tanaka, Sayaka ^{[2
]}

Morisaki, Tamami ^{[1
]}

Takashima, Tsutomu ^{[1
]}

Noda, Satoru ^{[1
]}

Onoda, Naoyoshi ^{[1
]}

Ohsawa, Masahiko ^{[2
]}

Hirakawa, Kosei ^{[1
]}

Ohira, Masaichi ^{[1
]}

机构：

[1] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan

[2] Osaka City Univ, Grad Sch Med, Dept Diagnost Pathol, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan

来源：

CANCERS | 2017年 / 9卷 / 01期

关键词：

triple-negative breast cancer; androgen receptor; prognostic marker; individualized treatment; intrinsic subtype; CELL-PROLIFERATION; SUBTYPES; BASAL; CHEMOTHERAPY; ESTROGEN;

D O I：

10.3390/cancers9010004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Triple-negative breast cancer (TNBC) has a poor prognosis because of frequent recurrence. Androgen receptor (AR) is involved in the pathogenesis of breast cancer, but its role is not clearly defined. The aim of this study was to explore the expression of AR and its relationship with clinicopathologic features in TNBC. Methods: This study investigated 1036 cases of sporadic invasive breast carcinoma. Immunohistochemical assays were performed to determine the expression of AR in 190 TNBC samples. The relationships between AR expression and clinicopathologic data and prognosis were analyzed. Results: In 190 TNBC cases, the prognosis of AR-positive patients was significantly better (p = 0.019, log-rank) than AR-negative patients, and in multivariate analysis, AR expression was an independent indicator of good prognosis (p = 0.039, hazard ratio = 0.36). In patients with disease relapse, AR positivity was significantly correlated with better prognosis (p = 0.034, log-rank). Conclusions: AR expression may be useful as a subclassification marker for prognosis in TNBC.

引用

收藏

页数：10

相关论文

共 37 条

[1] High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses [J].

Abd El-Rehim, DM ;

Ball, G ;

Pinder, SE ;

Rakha, E ;

Paish, C ;

Robertson, JFR ;

Macmillan, D ;

Blamey, RW ;

Ellis, IO .

INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (03) :340-350

[2] Breast cancer:: from estrogen to androgen receptor [J].

Andò, S ;

De Amicis, F ;

Rago, V ;

Carpino, A ;

Maggiolini, M ;

Panno, ML ;

Lanzino, M .

MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2002, 193 (1-2) :121-128

[3] Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer [J].

Asano, Yuka ;

Kashiwagi, Shinichiro ;

Onoda, Naoyoshi ;

Kurata, Kento ;

Morisaki, Tamami ;

Noda, Satoru ;

Takashima, Tsutomu ;

Ohsawa, Masahiko ;

Kitagawa, Seiichi ;

Hirakawa, Kosei .

BRITISH JOURNAL OF CANCER, 2016, 114 (01) :14-20

[4] Unusual presentation of myeloma in an elderly woman: Breast and cutaneous involvement [J].

Bauer, Carole ;

Peigne, Vincent ;

Gisselbrecht, Mathilde .

EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2008, 19 (02) :150-151

[5] Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers [J].

Castellano, Isabella ;

Allia, Elena ;

Accortanzo, Valeria ;

Vandone, Anna Maria ;

Chiusa, Luigi ;

Arisio, Riccardo ;

Durando, Antonio ;

Donadio, Michela ;

Bussolati, Gianni ;

Coates, Alan S. ;

Viale, Giuseppe ;

Sapino, Anna .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (03) :607-617

[6] Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide [J].

Cochrane, Dawn R. ;

Bernales, Sebastian ;

Jacobsen, Britta M. ;

Cittelly, Diana M. ;

Howe, Erin N. ;

D'Amato, Nicholas C. ;

Spoelstra, Nicole S. ;

Edgerton, Susan M. ;

Jean, Annie ;

Guerrero, Javier ;

Gomez, Francisco ;

Medicherla, Satyanarayana ;

Alfaro, Ivan E. ;

McCullagh, Emma ;

Jedlicka, Paul ;

Torkko, Kathleen C. ;

Thor, Ann D. ;

Elias, Anthony D. ;

Protter, Andrew A. ;

Richer, Jennifer K. .

BREAST CANCER RESEARCH, 2014, 16 (01)

[7]

DELAUNOIT Y, 1991, CANCER RES, V51, P5165

[8] Revising the role of the androgen receptor in breast cancer [J].

Fioretti, F. M. ;

Sita-Lumsden, A. ;

Bevan, C. L. ;

Brooke, G. N. .

JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2014, 52 (03) :R257-R265

[9] Androgen Receptor Status Is a Prognostic Marker in Non-Basal Triple Negative Breast Cancers and Determines Novel Therapeutic Options [J].

Gasparini, Pierluigi ;

Fassan, Matteo ;

Cascione, Luciano ;

Guler, Gulnur ;

Balci, Serdar ;

Irkkan, Cigdem ;

Paisie, Carolyn ;

Lovat, Francesca ;

Morrison, Carl ;

Zhang, Jianying ;

Scarpa, Aldo ;

Croce, Carlo M. ;

Shapiro, Charles L. ;

Huebner, Kay .

PLOS ONE, 2014, 9 (02)

[10] Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J].

Goldhirsch, A. ;

Wood, W. C. ;

Coates, A. S. ;

Gelber, R. D. ;

Thuerlimann, B. ;

Senn, H. -J. .

ANNALS OF ONCOLOGY, 2011, 22 (08) :1736-1747

← 1 2 3 4 →